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Abstract 
Objectives: To re-evaluate serum samples from our 2007 cohort of patients with  single episode 
isolated ON (SION), recurrent isolated ON (RION), chronic relapsing inflammatory optic neuropathy 
(CRION), multiple sclerosis-associated ON (MSON) and neuro-myelitis optica (NMO).  
 
Methods: We re-screened 103/114 patients with available serum on live cell based assays for 
AQP4-M23-IgG and MOG-1-IgG. Further testing included oligoclonal bands, serum levels of glial 
fibrillary acidic and neurofilament proteins and S100B. We show the impact of updated serology on 
these patients. 
 
Results: Reanalysis of our the original cohort revealed that AQP4-IgG seropositivity increased from 
56% to 75% for NMO, 5% to 22% for CRION, 6% to 7% for RION, 0% to 7% for MSON and 5% to 
6% for SION. MOG-IgG1 was identified in 25% of RION, 25% of CRION, 10% of SION, 0% of 
MSON and 0% of NMO. As a result patients have been reclassified incorporating their auto-
antibody status. Presenting visual acuity was significantly worse in patients who were AQP4-IgG 
seropositive only on CBA (p=0.034), but there was no relationship between antibody seropositivity 
and either ON relapse rate or visual acuity outcome.  
 
Conclusions: The number of patients with seronegative CRION and RION has decreased due to 
improved detection of autoantibodies over the past decade. It remains essential that the clinical 
phenotype guides both antibody testing and clinical management. Careful monitoring of the disease 
course is key  when considering whether to treat with prophylactic immune suppression.  
 
Key words: optic neuritis, CRION, NMO, aquaporin-4 (AQP4) antibody, myelin oligodendrocyte associated 
glycoprotein (MOG) antibody 
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Introduction 
In 2010 we reported the prevalence of NMO-IgG1in a cohort of patients with optic neuropathies in 
this journal [1]. NMO-IgG has subsequently been found to be identical to aquaporin-4 IgG (AQP4-
IgG). Subsequent developments have increased the sensitivity and specificity of the AQP4-IgG test 
[2][2; 3] . In addition, a relevant[4] auto-antibody was re-discovered which targets myelin-
oligodendrocyte glycoprotein (MOG) [5; 6]tmp[6] . Previously, we identified a subset of relapsing 
optic neuritis in which discrete acute attacks occur (recurrent isolated optic neuritis, RION); these 
cases resemble MS or NMO but without supporting evidence for either. This phenotype differs from 
the previously described chronic relapsing inflammatory optic neuropathy (CRION) [7] characterised 
by corticosteroid dependence or tendency to early relapse upon withdrawal of corticosteroids. In 
addition, there is emerging cross-sectional data that patients with both RION and CRION may be 
seropositive for MOG antibodies [8-10][8-11]tmp . The clinical phenotype of MOG-ON is 
heterogeneous [12-14] . The need for immunosuppression in patients with CRION strongly 
suggested an autoimmune pathology [15].  
 
In this study we revisited our original cohort [1] around 10 years later in order to investigate how the 
clinical diagnosis changed over time. Samples with remaining serum (103/114) were reanalysed for 
AQP4-IgG and MOG-IgG1 with state of the art live cell based assays (CBA) [6].  
 
Patients and Methods 
The clinical notes of 114 patients presenting with unilateral or bilateral isolated ON who had 
originally been recruited between November 1995 and September 2007 [1] were reviewed in 2017. 
The study was approved by the local and national ethics committees. Snellen visual acuities (VA) 
were converted to digital notation as described [16]. Patients were classified exactly as in our 
original report [1] according to clinical criteria and response to treatment into one of five 
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inflammatory optic neuropathies: multiple sclerosis associated optic neuritis (MSON), single-
episode isolated ON (SION), recurrent isolated ON (RION) CRION or NMO-ON [17] . 
Blood samples 
Aliquots of all serum samples were stored at -80°C. The samples were coded and send to the 
respective laboratories for analysis. Serum samples had been tested originally for NMO-
IgG1antibodies at the Mayo Clinic laboratories [2]. In 2015 they were re-tested for MOG-IgG1 at the 
Oxford Autoimmune Neurology Diagnostic Laboratory as described [9].  
Serum was available from 103/114 (91.4%) of the original samples, including all the AQP4 
seropositive samples; the remaining samples were consumed in previous studies. We have 
indicated In the table how many samples were available for each test at each time point and for 
each clinical subgroup. There were 30 missing samples for testing for MOG-IgG1. 
Cerebrospinal fluid (CSF) oligoclonal bands were determined using 2-4 µL of sample for isoelectric 
focusing (IEF) on agarose gels and quality control in the London laboratory as described [18]. 
Serum samples were also used to quantify protein biomarkers which have been related to 
astrocytic damage in NMO [19; 20] , glial fibrillary acidic protein (GFAP) and S100B using in-house 
developed ELISAs [21; 22] . Finally, neurofilament protein, a biomarker for neurodegeneration [23] , 
was quantified by in-house ELISA [24] . 
 
Data analysis 
Data analysis was performed using SAS (V9.4). Data distribution was non-Gaussian and therefore 
the median and interquartile ranges are shown. Categorical data were compared using the Chi-
square test; continuous data using the Kruskal-Wallis test. Correlation analysis was performed 
using Spearman’s R. A p-value of 0.05 was accepted as significant. All tests were two-sided. 
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Results 
In total 10 patients developed clinical definite multiple sclerosis, of whom 5 had originally presented 
as MSON, 2 as SION and 3 as RION. One patient with RION developed CRION. One patient with 
SION developed a progressive optic neuropathy (PON). One patient with SION (seronegative for 
AQP4-IgG and MOG-IgG), was later found to have a small perioptic nerve sheath meningioma 
which could not be seen on the initial imaging study. The single patient with SION who had 
developed NMO was seronegative for AQP4-IgG and MOG-IgG on all tests. There had been no 
change of the clinical diagnosis for patients with CRION and NMO. The patient characteristics with 
antibody data from 2007 and 2017 are shown in Table 1.  
No serum sample was positive for both AQP4-IgG and MOG-IgG1. There were no false positive 
NMO-IgG results in the 2007 data. 
AQP4-IgG was detected in six patients previously negative for NMO-IgG1including two MSON, 
three CRION and one NMO. The clinical phenotype of these patients remained unchanged, the 
diagnostic implications of the new autoantibody results are discussed in the next paragraph. MOG-
IgG was absent in MSON and NMO. MOG-IgG1 was found in 9% of SION, 20% of RION and 27% 
of CRION.  
 
New auto-antibody related classification 
Table 2 summarises the updated classification of our patient cohort which incorporates AQP4-IgG 
and MOG-IgG1 seropositivity. Two cases from the previous classification were excluded, one of 
whom had a perioptic nerve sheath meningioma and the second a progressive rather than 
relapsing optic neuropathy. By definition in the new group, MOG-ON only consists of patients 
(n=11) who were tested seropositive for MOG-IgG1. The NMO-ON group increased in numbers 
from 9 to 19. All other groups were reduced in numbers, MSON by 2, SION by 6, RION by 5 and 
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CRION by 7. 12 RION and 12 CRION patients remain without known auto-antibody status (missing 
samples for MOG-IgG in 8, see Table 1). 
There is a female predominance in all groups, greatest for RION (75%) and MOG-ON (73%), 
lowest for NMO (63%). There was a trend for MSON to be the youngest (33 years) and the SION 
and CRION to be the eldest (44 years). The age difference between groups did however not 
statistically significance due to small numbers and the large IQR range (p=0.18). 
VA at onset (p=0.08) or at follow-up(p=0.19) did not differ between groups. Finally, the number of 
ON relapses did not differ between RION, CRION, MSON, MOG-ON and NMO-ON (p=0.20). 
In the group of MOG-ON patients there was no significant correlation between the MOG titre and 
either demographic variables or baseline VA (p=0.77), follow-up VA (p=0.58) or number of ON 
relapses (p=0.34). Likewise, there was no statistical association for the dichotomised data, 
presence/absence of MOG-IgG1, and number of relapses, visual acuity or visual function outcome. 
The CSF investigations showed a low percentage of type 2 OCB (= true evidence for intrathecal 
IgG synthesis) (Table 3). More frequently there was presence of CSF IgG either in combination with 
evidence for systemic inflammation or as a monoclonal response (50% in RION and 45% in NMO-
ON, table 3).  
There was no significant difference in serum NfH, GFAP or S100B levels between the groups 
(Table 3). The highest individual serum GFAP levels were however seen in patients with NMO. 
Interestingly one patient who was classified clinically as NMO, but was seronegative both for NMO-
IgG1 (2007)and also AQP4-IgG (2017) had serum GFAP level of 2.71 ng/mL at baseline (October 
2004); she subsequently developed a longitudinally extensive transverse myelitis in 2015 at which 
time she also tested seropositive for AQP4-IgG on a new sample. Serum AQP4-IgG was of 
prognostic value because those patients who were tested AQP4-IgG positive had significantly 
worse VA at presentation  (VA 0.07±0.16) when compared to those who were AQP4-IgG 
seronegative (VA 0.19±0.29, p=0.034). This level of statistical significance was not observed at the 
time of our previous report for the NMO-IgG1 test (p=0.06). There was no association of either test 
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with the outcome VA or the number of relapses.  
 
 
Discussion 
The long term follow-up (up to 33 years) n patients presenting with different forms of optic neuritis 
[1] showed an increase in the autoantibody seropositivity rate from 9/114 (8%) to 26 (23%). 
Seropositivity in CRION increased from 1/19 (5%) to 7/18 (38%). These data are consistent with 
recent publications showing MOG-IgG1 in patients with CRION [4; 9; 10]. Our current report has 
the advantage of studying the original CRION cohort. We have been able to demonstrate changes 
in clinical status and serostatus over time with prolonged clinical follow-up and with improvement in 
sensitivity, spectrum and specificity of serologic diagnosis (Figure 1). Whilst the clinical phenotype 
of CRION remained in all patients, one of the CRION patients who was MOG-IgG1 seropositive 
had developed seizures. This is relevant because the association of MOG with seizures in optic 
neuritis has previously been reported [25]. Many more cases have since been recognised and 
importantly treatment with corticosteroids stopped seizures [25-30] .  
These results show clearly that the analytical sensitivity of the laboratory autoantibody tests has 
improved [1]. Importantly all patients with NMO were seronegative for MOG-IgG1 and the diagnosis 
of NMO remained unchanged at an averaged 10 year follow-up. The technical improvements 
include two main features. Firstly, live cell based assays are antigen specific with minimal 
background staining as only the outer surface of the cells are available for antibody binding. NMO-
IgG IHC uses tissue sections with nuclear and cytosolic determinants available as well as the 
complete repertoire of rodent brain antigens. Furthermore, the target of the assay is human 
recombinant antigen rather than rodent antigen. The newer MOG tests require rigorous, 
prospective validation [3; 31] and similar to what has happened to the testing for oligoclonal bands 
external quality control schemes are required [18; 32]. 
Although the analysis is based on evaluation of stored samples, IgG is quite stable for at least 25 
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years in appropriately stored samples [33]. Although not directly comparable between the two 
different assays, all NMO-IgG seropositive samples remained seropositive for AQP4-IgG and 14 
samples were seropositive on the newer tests suggesting that storage did not result in substantial 
loss of antibody reactivity. Whether or not IgG directed at MOG behaves different we are unable to 
tell from present data.  
All patients with a clinical diagnosis of CRION or NMO in our original report had been treated with 
chronic immunosupression regardless of autoantibody status [15]. The one patient with RION who 
converted to CRION was seronegative both for AQP4-IgG and MOG-IgG. Owing to the presence of 
significant numbers of individuals with these syndromes who are seronegative for both AQP4-IgG 
and MOG-IgG and lack other features of MS, our present clinical practice remains guided by the 
clinical phenotype in seronegative individuals. More data are needed to better understand the 
heterogeneous clinical presentations associated with MOG seropositivity [8; 9] . 
The heterogeneous clinical spectrum of MOG-ON is further highlighted by the observation of a wide 
range of VA data, both in the literature and in our cohort [9-11; 34-41]. VA outcome may be 
generally more favourable in patients with MOG-ON compared to those with NMO-ON and CRION, 
but this observation from the literature could not be confirmed in this cohort because of small 
patient numbers and high degree of variability. Furthermore, additional factors may need to be 
considered in interpreting visual outcomes, there is accumulating evidence for substantial inner 
retinal layer atrophy in MOG-ON patients [42; 43]. Large, collaborative, prospective cohort studies 
are required to appropriately address the prognostic implications of auto-antibody testing. It will be 
particularly important to distinguish patients with a mono-phasic disease course from those with a 
relapsing disease course. The latter group will require particularly careful management as there is a 
real risk of the cumulative damage of recurrent ON leading to blindness. In addition, MS targeted 
treatment might cause harm in patients with NMO-ON, CRION or MOG-ON [9; 15; 39]. 
A progressive optic neuropathy was eventually diagnosed in two cases who were both 
seronegative for AQP4- and MOG-IgG. In one case this was due to a perioptic meningioma which 
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was not visible on the initial dedicated orbital MRI sequences. In the other patient the disease 
course resembled a hereditary mitochondrial optic neuropathy, although neither genetic testing nor 
a muscle biopsy confirmed this. Nonetheless, when the course becomes progressive rather than 
relapsing, this raises concerns about either compression due to neoplasm or a neurodegenerative 
mechanism. 
Compared to the recent literature, the seropositivity rate for MOG-IgG in patients with CRION in our 
cohort (25%) is less than the 67-100% seropositivity rate reported by others [4; 11; 44][4]. 
Differences in study cohorts may be responsible; one was primarily paediatric (104 children, 7 
adults) [4]. In a South Korean cohort, 11/12 (92%) of patients initially classified as CRION were 
seropositive for MOG-IgG [11] and perineural enhancement of the optic nerve in 11/17 patients with 
MOG-ON [11]. We have observed similar findings in new MOG-ON cases. Likewise the Chinese 
CRION cohort shares similarities with present cohort regarding the poor visual outcome and MRI 
features, but has an equal gender balance, rather then the female predominance apparent in our 
CRION cohort [44]. Future studies should address the diagnostic specificity and sensitivity of this 
radiologic finding [11] in order to guide development of future diagnostic criteria.  
One limitation of this study was the inability to retest 11 patients for AQP4-IgG as there was 
insufficient serum. MOG-IgG1 could not be assessed in 30 patients, 18 of these had MSON, but 
this could be a contributing factor to the lower 25% MOG-ON prevalence rate. Likewise we cannot 
exclude that MOG-IgG is less stable than AQP4-IgG at -80C storage. Another limitation was that 
recruitment pre-dated the availability of OCT in clinical practice and we were not able to investigate 
previously observed associations of the antibody status and patterns of retinal layer swelling and 
atrophy [16]. An important shortcoming of present study is that MRI sequences used when we 
started to recruit patients with CRION over two decades ago did not permit for imaging at the same 
level of detail as contemporary sequences. Having recognised these early difficulties with orbital 
MRI the Queen Square team has contributed to improving the situation by implementation of 
dedicated sequences. One of the reasons in doing so was the original description of a distinct optic 
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nerve lesion pattern in NMO-ON compared to MSON [45]. Consequently, international consensus 
recommendations have been made regarding a dedicated MRI protocol for the investigation of optic 
neuritis [16]. Future studies should make use of such a consensus investigation protocol in order to 
further elucidate the specificity of MRI patterns in different forms of ON. 
 
In conclusion, the clinical phenotype of optic neuritis should continue to guide the clinical 
management. In patients with relapsing optic neuritis presence of AQP4-IgG and MOG-IgG renders 
a diagnosis of MS unlikely, and suggests that immunosuppression should be considered instead of 
other MS disease modifying treatments, although this recommendation remains based on expert 
opinion and not high levels of scientific evidence. There is a need for further research to identify the 
pathophysiology of CRION as many patients with presumed autoimmune pathology remain 
seronegative for currently known autoimmune targets. There is also a need for future multicentre 
treatment trials in patients with CRION, NMO-ON and MOG-ON which, because there are no 
published randomized clinical trials to inform treatment, and all are rare diseases requiring a 
collaborative network approach. 
 
 
Acknowledgement 
This research was supported by the National Institute for Health Research (NIHR) Biomedical 
Research Centre based at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of 
Ophthalmology. The views expressed are those of the author(s) and not necessarily those of the 
NHS, the NIHR or the Department of Health. We apologise to those authors whom we were not 
able to cite because of space limitations. 
 
 
Conflict of interest and source of funding 
 
A Petzold, M Woodhall, Z Khaleeli and GT Plant have no conflict of interest and nothing to disclose. 
This study was not funded.  
 
P Waters, A Vincent and the University of Oxford hold patents for antibody assays and have 
received royalties. P Waters has received honoraria from Biogen Idec, Mereo Biopharma, 
Page 12 
Retrogenix, UBC and Euroimmun AG; travel grants from the Guthy-Jackson Charitable Foundation; 
and research funding from Euroimmun AG. 
 
  
  
B Weinshenker receives royalties from RSR Ltd, Oxford University, Hospices Civil de Lyon, and 
MVZ Labor PD Dr. Volkmann und Kollegen GbR for a patent of NMO-IgG as a diagnostic test for 
NMO and related disorders. He serves as a member of an adjudication committee for clinical trials 
in NMO being conducted by MedImmune and Alexion pharmaceutical companies. He was a 
consultant for Caladrius Biosciences, Brainstorm Therapeutics, Roivant Sciences and Chugai 
Pharma regarding potential clinical trials for NMO. He serves as a member of a data safety 
monitoring committee for clinical trials conducted by Novartis. 
  
 
S. Pittock has intellectual property associated with the discovery of NMO-IgG, which has been 
licensed to a commercial entity. The NMO-IgG test is offered on a service basis by Mayo 
Collaborative Service Inc., an agency of Mayo Foundation. S. Pittock is a named inventor on 
patents (12/678,350 filed 2010 and 12/573,942 filed 2008) that relate to functional AQP4/NMO-IgG 
assays and NMO-IgG as a cancer marker; and receives research support from Alexion 
Pharmaceuticals, Inc., Medimmune LLC and Grifols. He has provided consultation to Alexion 
Pharmaceutical, MedImmune LLC, and Chugai Pharma, but has received no personal fees or 
compensation for these consulting activities. All compensation for consulting activities is paid 
directly to Mayo Clinic. 
 
 
Contributionship Statement 
Study design: GTP, AP. 
Laboratory work: MW, PW, AV, SP, OT, AP. 
Data collection: ZK, AP, MW, OT. 
Data analyses and interpretation: AP, GTP, PW, AV, BW, SP, OT, GTP. 
Manuscript writing: AP 
Manuscript revision: all co-authors.  
Page 13 
 
 
 
Table 1: The patient cohort according to 2007, clinical and MRI based. The patient characteristics 
are expressed as medians (interquartile range), numbers (%). 
 
Feature MSON SION RION CRION NMO 
N 28 41 17 19 9 
Age at onset (years) 33 (23-50) 42 (15-71) 37 (20-69) 45 (29-69) 29 (25-69) 
Female : Male 17:11 26:15 13:4 14:5 6:3 
NMO-IgG1(2007) 0/28 (0%) 2/41 (5%) 1/17 (6%)1 1/19 (5%) 5/9 (56%) 
AQP4-IgG (2017) 2/27 (7%) 2/34 (6%) 1/16 (7%) 1 4/18 (22%) 6/8 (75%) 
MOG -IgG1 (2017) 0/9 (0%) 4/40 (10%) 4/16 (25%) 3/12 (25%) 0/7 (0%) 
Follow-up (years) 8 (7-17) 8 (4-10) 12 (9-22) 11 (8-12) 11 (9-12) 
Revised 2017 diagnosis 4 RRMS 
1 SPMS2 
1 RRMS 
1 SPMS 
1 PON 
1 NMO 
2 RRMS 
1 SMPS 
1 CRION 
  
  1 perioptic 
meningioma 
   
 
 
  
                                                     
1 These patients have to be re-classified according to the auto-antibody status (see Table 2) 
 
2 This indicates the expected development from a Clinical Isolated Syndrome (CIS) MSON to clinical definite forms of 
MS, rather than a true changes of diagnosis. 
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Table 2: The 2017 classification of our patient cohort. The new classification incorporates the auto-
antibody status in addition to the clinical phenotype, long term clinical follow-up data and MRI. The 
patient characteristics are expressed as medians (interquartile range), numbers (%). 
 
Feature MSON SION RION CRION NMO-ON MOG-ON 
N 26 35 12 12 19 11 
Follow-up (years) 16 (5-25) 7 (3-11) 10 (8-10) 10 (8-12) 9 (8-12) 16 (5-25) 
Age at onset (years) 33 (30-42) 44 (32-50) 39 (27-45) 44 (36-52) 39 (26-48) 37 (30-55) 
Female : Male 17:9 23:12 9:3 8:4 12:7 8:3 
VA onset 0.10 
(0.03-0.29) 
0.10 
(0.01-0.25) 
0.05 
(0-0.10) 
0.01 
(0-0.17) 
0.01 
(0-0.01) 
0.03 
(0-0.17) 
VA follow-up 0.67 
(0.33-1.00) 
0.38 
(0.10-1.00) 
0.25 
(0.10-0.67) 
0.17 
(0.02-0.50) 
0.17 
(0-0.67) 
0.58 
(0.10-0.67) 
ON relapses 3 (2.5-5) 0 (0-0) 4.5 (4-7) 2 (2-4.5) 1 (0-4) 1 (0-6) 
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Table 3: Paraclinical tests in the 2017 classification of our patient cohort. 
 
Feature MSON SION RION CRION NMO-ON MOG-ON 
Time to sample (days) 0  
(0-4) 
275 
(0-933) 
1069  
(0-1810) 
78  
(0-803) 
842 
(0-1810) 
1069 
(0-2072) 
CSF OCB type 23 1/5 (20%) 3/9 (33%) 0 0 2/11 (18%) 0 
CSF OCB other4 2/5 (40%) 3/9 (33%) 2/4 (50%) 2/6 (33%) 5/11 (45%) 1/7 (14%) 
Serum NfH [ng/mL] 0.07 
(0.04-0.16) 
0.17 
(0.04-0.24) 
0.11 
(0-04-0.18) 
0.09 
(0.01-0.27) 
0.07 
(0.03-0.16) 
0.06 
(0.04-0.16) 
Serum GFAP [ng/mL] 0 0.75 
(0.03-1.47) 
0 0.63 
(0.09-0.88) 
0.67 
(0.24-2.24) 
0.34 
(0-0.67) 
Serum S100B [ng/mL] 0 0.06 
(0.03-0.08) 
0 0.02 
(0.01-0.05) 
0 
(0-0.08) 
0.01 
(0-0.01) 
AQP4-IgG (2017) 0 0 0 0 15/175 (79%) 0 
MOG -IgG1 (2017) 0 0 0 0 0 11 (100%) 
  
                                                     
3 The OCB type 2 pattern indicates intrathecal IgG synthesis and has been incorporated in the 2017 revision of the 
McDonald criteria for MS. Typically the type 2 pattern is referred to as “oligoclonal bands” being present. The 
percentages (%) shown were calculated from the total number of CSF samples with matched serum samples. 
4 There is a whole range of other diseases where IgG can be demonstrated in the CSF either monoclonal or 
oligoclonal with some bands also being present in the matched serum sample [18] .  
5 Sample not available in two cases. 
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Figure 1: Breakdown of the original CRION cohort over time into specific auto-antibody mediated sub-groups. This 
flow chart illustrates how a well characterised clinical phenotype of a rare disease permits for prospective interogation 
of new molecular targets of an autoimmune attack. 
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